China Isotope & Radiation Corporation (1763) H1 2024 earnings summary

Executive summary

• Revenue for the first half of 2024 increased by 2.6% year-over-year to RMB2,810.3 million, with net profit up 8.7% to RMB306.7 million and profit attributable to equity shareholders up 23.2%.

• Pharmaceuticals remained the largest segment, contributing 62.9% of revenue and 81% of gross profit, despite a slight revenue decline due to centralized procurement.

• Growth was driven by increased market development, especially in radioactive source products, irradiation, and other business segments.

• The company advanced R&D, completed new production lines for lutetium-177 and gallium-68, and expanded international business, including its first overseas EPC project in Bangladesh.

Financial highlights

• Revenue: RMB2,810.3 million (up 2.6% year-over-year).

• Gross profit: RMB1,464.2 million (down 1.4% year-over-year); gross margin decreased to 52.1% from 54.2%.

• Net profit: RMB306.7 million (up 8.7% year-over-year).

• Basic/diluted EPS: RMB0.48 (up from RMB0.39 year-over-year).

• Net current assets increased 3.2% to RMB4,065.2 million.

Outlook and guidance

• The company aims to leverage favorable national policies and industry growth, focusing on innovation, capacity expansion, and internationalization.

• Plans to accelerate construction of pharmaceutical centers and irradiation bases, and to enhance management effectiveness and compliance.

• Focus on strengthening R&D, expanding production capacity, and accelerating domestic substitution in nuclear medical equipment.